Tonix Pharmaceuticals stock halted ahead of FDA approval news
William Guyer, Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), sold 35,007 shares of common stock on August 8, 2025, for $71.77, totaling approximately $2.5 million. The sale was executed under a prearranged 10b5-1 trading plan adopted November 27, 2024. The transaction comes as Corcept, now valued at $7.76 billion, has delivered an impressive 115% return over the past year. According to InvestingPro analysis, the company maintains a GREAT financial health score.
On the same day, Guyer also exercised options to acquire 35,007 shares of Corcept Therapeutics common stock at an exercise price of $21.65, for a total value of $757901. Following these transactions, Guyer directly owns 5,487 shares of Corcept Therapeutics. The stock currently trades at a P/E ratio of 57.6, near its 52-week high of $117.33, reflecting strong market confidence in the company’s growth prospects.
In other recent news, Corcept Therapeutics announced its Q2 2025 earnings, showcasing a notable earnings per share (EPS) beat. The company reported an EPS of $0.29, surpassing the forecasted $0.19 by 52.63%. However, the revenue figures were slightly below expectations, coming in at $194.4 million compared to the anticipated $199.4 million, marking a 2.51% shortfall. These results reflect ongoing supply chain challenges faced by the company. Despite the positive EPS, the revenue miss has been a point of concern for investors. The earnings announcement did not include any major mergers or acquisitions. Analysts have not provided any recent upgrades or downgrades for Corcept Therapeutics. These developments offer insights into the company’s current financial standing and challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.